First Annual DealFlow Event in NYC Brings Together Industry Participants and Potential Regulators

Last Thursday, DealFlow Events held their first annual Litigation Funding Forum in New York City. Industry participants gathered at the TKP Conference Center in midtown Manhattan to network and discuss the most pressing issues facing the industry today.

The opening panel, titled “State of the Litigation Funding Market,” featured a diverse cross-section of industry participants. Moderator Ben Ruzow of distressed investment firm Argo Partners, and panelists John Kelly, Managing Director of the American Legal Finance Association (ALFA), Jake Cantrell of law firm lender Armadillo Partners, and Scott Mozarsky of litigation funder Vannin Capital shared the dais.

The first question focused on the role that public policy plays in the litigation finance industry, and actually kicked off a bit of a back-and-forth between two of the panelists. John Kelly underscored the notion of certainty when it comes to securitization. Capital markets want to know “am I participating in an asset class that will be around in 20 years?” As a result, the greatest risk in regard to public policy is headlines. Bad headlines (in some cases driven by industry opponents) can influence policymakers who simply don’t understand how the industry works, or don’t even know that the industry exists (this turned out to be a prescient statement – more on that below).

In response, Scott Mozarsky of Vannin Capital countered that although there have been some minor policy setbacks in states like Wisconsin and West Virginia, overall the regulatory push has been unsuccessful. Clearly, the issue of disclosure is what’s in play at the moment (as opposed to issues around work product and confidentiality, which have basically been resolved), but given the limited imposition of mandatory disclosure by state legislatures, “I wouldn’t call the Chamber’s efforts successful,” Mozarsky said (alluding to the U.S. Chamber of Commerce, which is the entity behind the regulatory push).

Yet Kelly took issue with Mozarsky’s point of view, claiming that while the impact so far has been minimal, any trend towards regulation can be enough to instill anxiety in the hearts of prospective investors. “If you look at the last 15 years, there’s been no law on [litigation funding]. Now over the last couple of years two states have a law. So capital markers look at that and say, ‘Is there certainty?’ There was certainty for a long time, but now it’s changing.”

Mozarsky then highlighted Vannin’s position on disclosure, which is that limited disclosure be mandated in all cases (‘limited disclosure’ being disclosure of the fact of a funding agreement, and the identity of the funder), but any further disclosure – such as the terms or cost of capital – be expressly prohibited. As discussed in a recent podcast episode on LFJ, Vannin views this compromise as a means of nipping the regulatory push in the bud, by landing on a comfortable middle ground that will likely be the end result of all of this lobbying anyway.

At this point, Jake Cantrell jumped in and offered up a fresh perspective: that it’s not just about disclosure, but what’s done with the disclosure. In international arbitration for example, if disclosure is mandated, that could be used to force the claimant to post a $10MM bond in order to proceed. If there are multiple claims pending, that can add up to a pretty hefty capital commitment, even for a large firm.

Everyone on the dais agreed.

In the end, when Ruzow asked panelists where they see things headed in the space as relates to regulation, Kelly reaffirmed his position that change is on the horizon. The Chamber is continuing its push, and while he doesn’t see federal legislation being a threat, he worries that regulation is moving through the states and could impact the prospect of securitization, simply due to uncertainty. Kelly also pointed out that there is a greater risk for the commercial side, since consumer funding has already been in play for a long time, so it has been examined and reexamined extensively. Commercial funding is getting looked at with a fresh set of eyes, and therefore the outcome is less predictable. Kelly suggested that both consumer and commercial funders join forces and work in concert to push back against the Chamber. “The enemy of my enemy is my friend,” he exclaimed.

It’s worth noting that there are currently two lobbying organizations on the consumer side, and none on the commercial side (at least not in the U.S.). It will be interesting to see if funders take up Kelly’s call to arms, and join forces across industry lines.

Ruzow then turned to the issue of defense-side funding. Scott Mozarsky pointed to three instances where defense funding has come into play. The most basic is where an asset is involved, in that a company is sued over the rights to a patent or JV. Funders can back the case for a portion of the asset over a certain period of time, or up to a certain benchmark. The second is portfolio funding, where funders may do deals with large multinationals and fund 3-5 claims. Most of those are plaintiff-side funding, but the funder may offer up a defense-side claim as a loss-leader of sorts, assuming the funder believes the plaintiff-side claims will cover the defense-side fees and expenses. The third example is perhaps the most complex: this would be a situation where “winning is defined as losing less.” In other words, say a company is sued for $1bn. Counsel may know that number is absurd, yet they may assess that the company is on the hook for something on the order of $200MM. In that case, they may secure funding with the aim of “losing less,” and the funder would take a piece of the delta between the two numbers. It’s unclear how many of these defense-side structures have so far been implemented, but it is extremely interesting to hear how they can be positioned.

For the final segment of the first panel, Mozarsky was asked about the state of Legal Technology. After deftly plugging his latest podcast episode on LFJ where he discussed that very topic (check is in the mail–), Mozarsky explained that while the predictive analytics aren’t quite there yet, AI can help benchmark law firms and jurisdictions. “Analytics are being used for development purposes and to assess risk around cases,” Mozarsky said. “That will only grow and grow. The data is getting stronger, and we’re witnessing an acceleration in the space as Tech firms enhance their products to meet the needs of the industry.”

Both Cantrell and Kelly agreed, stating that predictive analytics is the future of the industry, and also not that far away.

The first panel provided a nice overview of the industry as a whole, and paved the way for the next pair of speakers at the event. First up was New York State Senator Robert Ortt. Ortt, who represents the Buffalo and Niagara Falls region, was due to speak in person, but inclement weather prevented his plane from taking off, so he delivered his speech via Skype. Ortt isn’t the most beloved figure in litigation funding circles, given that he has put forth legislation which seeks to cap rates on funding agreements, among other things. So it was interesting to have him participate at the event.

Ortt began by explaining that he first learned of litigation funding through news stories he read in the New York Times and New York Post. This seems to validate John Kelly’s earlier point that headline risk is the greatest threat to litigation funding where public policy is concerned. Indeed, here was a legislator admitting to a room full of funders that his introduction to the industry was via the negative news stories in the press.

That said, Ortt seemed to strike a conciliatory tone. He admitted that he took an openly hostile stance against the industry, but has since learned that there are many benefits to funding, and so his position has softened – at least a little. Ortt framed his bill – SB 4555 – as one the industry can and should get behind. The bill issues a maximum cap of 36% on rates charged by funders. It also allows for fees to be charged, and for the assignment of financing. Ortt asserts that his bill is more robust than SB 4478 – a similar bill that has been proposed – which doesn’t allow for those measures, and seeks to mandate a 25% annual maximum rate.

According to Ortt, regulation should be enacted in order to keep bad actors out of the litigation funding game. Should one or two of those bad actors make headlines, legislation could come down that’s far more onerous. “If we don’t regulate,” Ortt warned, “I worry about an agency that comes along that is far too intrusive. In Indiana, both sides came together because they saw what happened in Arkansas.” In other words, the funding community should get on board with legislation because in the long run, it is in the funding community’s own best interest to be regulated. “The goal is to take ‘predatory’ out of this industry,” Ortt insisted.

There were no questions after Ortt finished speaking. One could surmise any number of reasons why.

Eric Schuller, President of the Alliance for Responsible Consumer Legal Funding, one of the two consumer funding lobbyist organizations, spoke directly after Ortt. Schuller began by clearly illustrating all of the states where legislation has taken place, and exactly what type of legislation has been implemented.

Indiana, Arkansas, Tennessee and now West Virginia have rate caps. The first two at 36% + 7% (fees), with Arkansas at 17% and West Virginia at 18%. Wisconsin and West Virginia have mandated disclosure, and Nebraska, Vermont and Maine have mandated that funders must disclose to regulators what their rates are. There have also been numerous states where legislation was introduced (though not passed) which sought to cap rates. Alabama, Missouri, Rhode Island, New Jersey and yes, even New York, all fall under that category. New York even had a bill which sought to place funding under The Martin Act, thereby making it a criminal activity.

On the issue of disclosure, Schuller agreed with John Kelly from the first panel, in that the two states which passed legislation recently are ‘innocuous’ in and of themselves, however, the fact that they passed legislation at all proves that The Chamber of Commerce is gaining traction. Schuller also pointed out that the Wisconsin and West Virginia bills were purposefully vague on the issue of disclosure, in that they don’t stipulate specifics, just that funding must be disclosed. A similar bill was recently introduced in Florida, so Schuller sees a trend forming. Texas has also introduced a bill which would leave the issue of disclosure up to the Supreme Court. That bill is held up in committee.

When asked if he would support any rate cap at all – ostensibly in rebuttal to Sen. Ortt’s proposed 36% cap – Schuller pointed out that any cap arbitrarily squeezes out all consumers whose risk profiles place them above that rate. His industry can survive within certain high rate caps, but in the states that have implemented those, there has been a marked decrease of industry activity, and that hurts consumers.

Admittedly, it would have been nice to see Schuller spar with Ortt in person, perhaps via some direct Q&A from one to the other. Alas, due to inclement weather, it was not to be.

The event continued with additional panels, from “Litigation Funding in Class Actions vs. Arbitration” to “Comparison Shopping: What Counsel Should Look for in Identifying the Right Litigation Financing Firm for Their Clients.” In the former, Lisa Richman of McDermott Will and Emery and J. Richard Supple of Hinshaw and Culbertson explained how arbitration funding poses certain unique challenges. For example, contrary to popular belief, arbitrations aren’t confidential, they are private. The distinction being that (unless otherwise stipulated by the parties), each party can disclose information about an arbitration publicly. Given that reality, there is a concern about how much information should be shared with a funder in an arbitration matter. The latter panel featured a broad swathe of funders, as well as one law firm. They discussed the issue of commoditization, and how funders will need to differentiate along lines of relationship building and flexibility of terms. Much of the funding process boils down to communication and trust. “It’s like dating,” one of the panelists said. I, for one, am waiting for Litigation Funding Tinder app…

All told, the DealFlow event provided an opportunity to assess the current state of the industry, and hash out some differences between funders and industry experts on a range of topics. It was nice to see the appearance of an industry opponent (though Sen. Ortt would likely classify himself as a proponent of the industry, albeit a more regulated industry). And it was valuable to see an exact breakdown of industry regulation by state, as delivered by Eric Schuller.

So here’s looking forward to the next DealFlow event. I am told one is already in the works for 2020.

Commercial

View All
Community Spotlights

Community Spotlight: Dr. Detlef A. Huber, Managing Director, AURIGON LRC

By John Freund |

Detlef is a German attorney, former executive of a Swiss reinsurance company and as head of former Carpentum Capital Ltd. one of the pioneers of litigation funding in Latin America. Through his activities as executive in the insurance claims area and litigation funder he gained a wealth of experience in arbitrations/litigations in various businesses. He is certified arbitrator of ARIAS US and ARIAS UK (AIDA Reinsurance and Insurance Arbitration Society) and listed on the arbitrators panel of DIS (German Arbitration Institute).

He studied law in Germany and Spain, obtained a Master in European Law (Autónoma Madrid) and doctorate in insurance law (University of Hamburg).

Detlef speaks German, Spanish, English fluently and some Portuguese.

Company Name and Description:  AURIGON LRC (Litigation Risk Consulting) is at home in two worlds: dispute funding and insurance. They set up the first European litigation fund dedicated to Latin America many years ago and operate as consultants in the re/insurance sector since over a decade.

Both worlds are increasingly overlapping with insurers offering ever more litigation risk transfer products and funders recurring to insurance in order to hedge their risks. Complexity is increasing for what is already a complex product.

Aurigon acts as intermediary in the dispute finance sector and offers consultancy on relevant insurance matters.

Company Website: www.aurigon-lrc.ch

Year Founded: 2011, since 2024 offering litigation risk consulting  

Headquarters: Alte Steinhauserstr. 1, 6330 Cham/Zug Switzerland

Area of Focus:  Litigation funding related to Latin America and re/insurance disputes

Member Quote: “It´s the economy, stupid. Not my words but fits our business well. Dont focus on merits, focus on maths.”

Read More

Manolete Partners Releases Half-Year Results for the Six Months Ended 30 September 2024

By Harry Moran |

Manolete (AIM:MANO), the leading UK-listed insolvency litigation financing company, today announces its unaudited results for the six months ended 30 September 2024. 

Steven Cooklin, Chief Executive Officer, commented: 

“These are a strong set of results, particularly in terms of organic cash generation. In this six-month period, gross cash collected rose 63% to a new record at £14.3m. That strong organic cash generation comfortably covered all cash operating costs, as well as all cash costs of financing the ongoing portfolio of 413 live cases, enabling Manolete to reduce net debt by £1.25m to £11.9m as at 30 September 2024. 

As a consequence of Manolete completing a record number of 137 case completions, realised revenues rose by 60% to a further record high of £15m. That is a strong indicator of further, and similarly high levels, of near-term future cash generation. A record pipeline of 437 new case investment opportunities were received in this latest six month trading period, underpinning the further strong growth prospects for the business. 

The record £14.3.m gross cash was collected from 253 separate completed cases, highlighting the highly granular and diversified profile of Manolete’s income stream. 

Manolete has generated a Compound Average Growth Rate of 39% in gross cash receipts over the last five H1 trading periods: from H1 FY20 up to and including the current H1 FY25. The resilience of the Manolete business model, even after the extraordinary pressures presented by the extended Covid period, is now clear to see. 

This generated net cash income of £7.6m in H1 FY25 (after payment of all legal costs and all payments made to the numerous insolvent estates on those completed cases), an increase of 66% over the comparative six-month period for the prior year. Net cash income not only exceeded by £4.5m all the cash overheads required to run the Company, it also exceeded all the costs of running Manolete’s ongoing 413 cases, including the 126 new case investments made in H1 FY25. 

The Company recorded its highest ever realised revenues for H1 FY25 of £15.0m, exceeding H1 FY24 by 60%. On average, Manolete receives all the cash owed to it by the defendants of completed cases within approximately 12 months of the cases being legally completed. This impressive 60% rise in realised revenues therefore provides good near-term visibility for a continuation of Manolete’s strong, and well-established, track record of organic, operational cash generation. 

New case investment opportunities arise daily from our wide-ranging, proprietary, UK referral network of insolvency practitioner firms and specialist insolvency and restructuring solicitor practices. We are delighted to report that the referrals for H1 FY25 reached a new H1 company record of 437. A 27% higher volume than in H1 FY24, which was itself a new record for the Company this time last year. That points to a very healthy pipeline as we move forward into the second half of the trading year.” 

Financial highlights: 

  • Total revenues increased by 28% to £14.4m from H1 FY24 (£11.2m) as a result of the outstanding delivery of realised revenues generated in the six months to 30th September 2024.
    • Realised revenues achieved a record level of £15.0m in H1 FY25, a notable increase of 60% on H1 FY24 (£9.4m). This provides good visibility of near-term further strong cash generation, as on average Manolete collects all cash on settled cases within approximately 12 months of the legal settlement of those cases
    • Unrealised revenue in H1 FY25 was £(633k) compared to £1.8m for the comparative H1 FY24. This was due to: (1) the record number of 137 case completions in H1 FY25, which resulted in a beneficial movement from Unrealised revenues to Realised revenues; and (2) the current lower average fair value of new case investments made relative to the higher fair value of the completed cases. The latter point also explains the main reason for the marginally lower gross profit reported of £4.4m in this period, H1 FY25, compared to £5.0m in H1 FY24. 
  • EBIT for H1 FY25 was £0.7m compared to H1 FY24 of £1.6m. As well as the reduced Gross profit contribution explained above, staff costs increased by £165k to £2.3m and based on the standard formula used by the Company to calculate Expected Credit Losses, (“ECL”), generated a charge of £140k (H1 3 FY24: £nil) due to trade debtors rising to £26.8m as at 30 September 2024, compared to £21.7m as at 30 September 2023. The trade debtor increase was driven by the outstanding record level of £15.0m Realised revenues achieved in H1 FY25.
  • Loss Before Tax was (£0.2m) compared to a Profit Before Tax of £0.9m in H1 FY24, due to the above factors together with a lower corporation tax charge being largely offset by higher interest costs. 
  • Basic earnings per share (0.5) pence (H1 FY24: 1.4 pence).
  • Gross cash generated from completed cases increased 63% to £14.3m in the 6 months to 30 September 2024 (H1 FY24: £8.7m). 5-year H1 CAGR: 39%.
  • Cash income from completed cases after payments of all legal costs and payments to Insolvent Estates rose by 66% to £7.6m (H1 FY24: £4.6m). 5-year H1 CAGR: 46%.
  • Net cashflow after all operating costs but before new case investments rose by 193% to £4.5m (H1 FY24: £1.5m). 5-year H1 CAGR: 126%.
  • Net assets as at 30 September 2024 were £40.5m (H1 FY24: £39.8m). Net debt was reduced to £11.9m and comprises borrowings of £12.5m, offset by cash balances of £0.6m. (Net debt as 31 March 2024 was £12.3m.)
  • £5m of the £17.5m HSBC Revolving Credit Facility remains available for use, as at 30 September 2024. That figure does not take into account the Company’s available cash balances referred to above.

Operational highlights:

  • Ongoing delivery of record realised returns: 137 case completions in H1 FY25 representing a 18% increase (116 case realisations in H1 FY24), generating gross settlement proceeds receivable of £13.9m for H1 FY25, which is 51% higher than the H1 FY24 figure of £9.2m. This very strong increase in case settlements provides visibility for further high levels of cash income, as it takes the Company, on average, around 12 months to collect in all cash from previously completed cases.
  • The average realised revenue per completed case (“ARRCC”) for H1 FY25 was £109k, compared to the ARRCC of £81k for H1 FY24. That 35% increase in ARRCC is an important and an encouraging Key Performance Indicator for the Company. Before the onset and impact of the Covid pandemic in 2020, the Company was achieving an ARRCC of approximately £200k. Progress back to that ARRCC level, together with the Company maintaining its recent high case acquisition and case completion volumes, would lead to a material transformation of Company profitability.
  • The 137 cases completed in H1 FY25 had an average case duration of 15.7 months. This was higher than the average case duration of 11.5 months for the 118 cases completed in H1 FY24, because in H1 FY25 Manolete was able to complete a relatively higher number of older cases, as evidenced by the Vintages Table below.
  • Average case duration across Manolete’s full lifetime portfolio of 1,064 completed cases, as at 30 September 2024 was 13.3 months (H1 FY24: 12.7 months).
  • Excluding the Barclays Bounce Back Loan (“BBL”) pilot cases, new case investments remained at historically elevated levels of 126 for H1 FY25 (H1 FY24: 146 new case investments).
  • New case enquiries (again excluding just two Barclays BBL pilot cases from the H1 FY24 figure) achieved another new Company record of 437 in H1 FY25, 27% higher than the H1 FY24 figure of 343. This excellent KPI is a strong indicator of future business performance and activity levels.
  • Stable portfolio of live cases: 413 in progress as at 30 September 2024 (417 as at 30 September 2023) which includes 35 live BBLs.
  • Excluding the Truck Cartel cases, all vintages up to and including the 2019 vintage have now been fully, and legally completed. Only one case remains ongoing in the 2020 vintage. 72% of the Company’s live cases have been signed in the last 18 months.
  • The Truck Cartel cases continue to progress well. As previously reported, settlement discussions, to varying degrees of progress, continue with a number of Defendant manufacturers. Further updates will be provided as concrete outcomes emerge.
  • The Company awaits the appointment of the new Labour Government’s Covid Corruption Commissioner and hopes that appointment will set the clear direction of any further potential material involvement for Manolete in the Government’s BBL recovery programme.
  • The Board proposes no interim dividend for H1 FY25 (H1 FY24: £nil).

The full report of Manolete’s half-year results can be read here.

Read More

LegalPay’s CIO Highlights the Opportunities and Challenges for Defense-Side Funding

By Harry Moran |

As the legal funding industry has matured and become a mainstream feature of many jurisdictions’ legal systems, funders are increasingly looking at ways to diversify their activities.

In an article for Insolvency Tracker, Tanya Prasad, CIO of LegalPay, addresses the niche topic of defense-side funding and examines whether there is potential for this type of legal funding to grow in the same way that plaintiff funding has over recent years. Prasad notes that in an environment where “the demand for risk management tools in litigation grows”, large corporations may look to third-party funders to help supplement legal budgets “while potentially achieving favourable outcomes”.

Prasad acknowledges that compared to traditional plaintiff-side funding, defense-side funding “comes with unique challenges”. Whilst claimants may seek to maximise their financial returns in the form of damages and compensation, a defendant will “generally focus on minimizing loss exposure.” As a result of this difference in goals, Prasad suggests that funders would need to not only “employ creative pricing structures”, but would also need to find new metrics to define success.

The latter point is one that Prasad argues is key to creating a viable defense-side funding ecosystem, noting that “establishing a clear definition of success” may have different parameters for different defendants. Examples of this could include structuring funding agreements to incorporate “avoided loss” measures, which would define success based on “achieving a favorable settlement or dismissal at a lower financial cost than anticipated.”

If these difficulties that Prasad highlights can be overcome, she suggests that “defense-side litigation funding has the potential to redefine legal finance, supporting fair representation for both plaintiffs and defendants and expanding access to justice across the board.” Additionally, Prasad points to a handful of examples where defense-side funding has been successfully employed, such as the Gillette v. ShaveLogic case, where Burford Capital provided funding for the defendant to successfully oppose Gillette’s claims of trades secret misappropriation and unfair competition.